New and Novel Treatments for Gynecologic CancerImmunotherapy for Gynecologic Cancer: Current Applications and Future DirectionsLYNAM, SARAH MD*; LUGADE, AMIT A. PhD, MBA†; ODUNSI, KUNLE MD, PhD*,†Author Information *Department of Gynecologic Oncology †Center for Immunotherapy Roswell Park Comprehensive Cancer Center, Buffalo, New York The authors declare that they have nothing to disclose. Correspondence: Kunle Odunsi, MD, PhD, Roswell Park Comprehensive Cancer Center, Buffalo, NY. E-mail: firstname.lastname@example.org Clinical Obstetrics and Gynecology: March 2020 - Volume 63 - Issue 1 - p 48-63 doi: 10.1097/GRF.0000000000000513 Buy Metrics Abstract The role of the immune system in the development of cancer has been a subject of ongoing clinical investigation in recent years. Emerging data demonstrate that tumorigenesis resulting in ovarian, uterine, and cervical cancers is a consequence of impaired host immune responses to cancerous cells. Leveraging the immune system through the use of immune checkpoint inhibitors, therapeutic vaccine therapy, and adoptive cell transfer presents a profound opportunity to revolutionize cancer treatment. This review will encompass the role of the immune system in development of gynecologic cancers and highlight recent data regarding immunotherapy applications in ovarian, uterine, and cervical cancers. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.